Abstract:Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among early-onset AF patients (∼4%–11%), most notably for cardiomyopathy genes in which rare variants are considered clinically actionable. Genetic testing thus presents a promising opportunity to identify monogenetic defects linked to AF and inherited cardiac conditions, such as cardiomyopathy, and may contribute to prognosis and management in early-onset AF patients. A first step towards recognizing this monogenic contribution was taken with the Class IIb recommendation for genetic testing in AF patients aged 45 years or younger by the 2023 American College of Cardiology/American Heart Association guidelines for AF. By identifying pathogenic genetic variants known to underlie inherited cardiomyopathies and arrhythmia syndromes, a personalized care pathway can be developed, encompassing more tailored screening, cascade testing, and potentially genotype-informed prognosis and preventive measures. However, this can only be ensured by frameworks that are developed and supported by all stakeholders. Ambiguity in test results such as variants of uncertain significance remain a major challenge and as many as ∼60% of people with early-onset AF might carry such variants. Patient education (including pretest counselling), training of genetic teams, selection of high-confidence genes, and careful reporting are strategies to mitigate this. Further challenges to implementation include financial barriers, insurability issues, workforce limitations, and the need for standardized definitions in a fast-moving field. Moreover, the prevailing genetic evidence largely rests on European descent populations, underscoring the need for diverse research cohorts and international collaboration. Embracing these challenges and the potential of genetic testing may improve AF care. However, further research—mechanistic, translational, and clinical—is urgently needed. In people with early-onset atrial fibrillation (AF), an enrichment in pathogenic or likely pathogenic variants in cardiomyopathy and or/arrhythmia syndrome-associated genes is observed (see Figure 2 for more details). The diagnostic yield of capturing people with variants in these genes is higher with younger age, family history, structural or electrocardiogram (ECG) abnormalities (see Figure 1 for more details). Uncovering these high-risk individuals for heart failure enables personalized management that will need to comprehensively assess potential risks and benefits of genetic testing results. Some benefits include genotype-informed clinical assessment such as reinterpretation of borderline left ventricular hypertrophy in the setting of hypertrophic cardiomyopathy variants as well as genetic counselling and cascade testing of family members. Potential risks include the high likelihood of variants of uncertain significance that may lead to anxiety without informing healthcare decisions. Resource constraints in clinical settings might lead to further inequity for people without access to academic centres with the necessary infrastructure to offer such genetic testing services or genetic counselling (see Figure 3 for more details).

The Genetics of Atrial Fibrillation: from the Bench to the Bedside.

Genetics and Pharmacogenetics of Atrial Fibrillation: A Mechanistic Perspective

Atrial Fibrillation Genetic Considerations: The Basic Scientist'S Perspective

Pathophysiology, molecular mechanisms, and genetics of atrial fibrillation

Epigenetic Mechanism and Therapeutic Implications of Atrial Fibrillation

Genetic basis of atrial fibrillation.

Common variants for atrial fibrillation: results from genome-wide association studies

Advances in Basic and Translational Research in Atrial Fibrillation.

Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective

Epidemiology and natural history of atrial fibrillation: clinical implications.

Potential Target Genes in the Development of Atrial Fibrillation: A Comprehensive Bioinformatics Analysis

Atrial fibrillation variant-to-gene prioritization through cross-ancestry eQTL and single-nucleus multiomic analyses

A Network and Pathway Analysis of Genes Associated With Atrial Fibrillation

Identification of potential crucial genes in atrial fibrillation: a bioinformatic analysis

Genetic basis of atrial fibrillation opyright

Mapping a Novel Locus for Familial Atrial Fibrillation on Chromosome 10P11-Q21.

Genetic testing in early-onset atrial fibrillation

Gene Polymorphism and Recurrent Atrial Fibrillation after Catheter Ablation: A Comprehensive Review.

Single-cell Genomics Improves the Discovery of Risk Variants and Genes of Atrial Fibrillation.

Molecular Basis Of Gene-Gene Interaction: Cyclic Cross-Regulation Of Gene Expression And Post-Gwas Gene-Gene Interaction Involved In Atrial Fibrillation

Abstract 4141076: Shared Genetic Characteristics and Molecular Mechanisms Between Atrial Fibrillation and Aortic Valve Calcification: Insights from Transcriptome Data